SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fatal Sigal

(Last)

(First)

(Middle)

C/O CHEMOMAB THERAPEUTICS LTD.

10 HABARZEL ST., BUILDING C, 10TH FLOOR

(Street)

TEL AVIV

6158101

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [ CMMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	9,728	D
American Depositary Shares⁽¹⁾	15,222	D
American Depositary Shares⁽²⁾	12,500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock option (right to buy American Depositary Shares)	⁽³⁾	11/11/2031	American Depositary Shares	8,900	$39.31	D
Stock option (right to buy American Depositary Shares)	⁽⁴⁾	11/08/2032	American Depositary Shares	7,350	$8.44	D
Stock option (right to buy American Depositary Shares)	⁽⁵⁾	06/14/2033	American Depositary Shares	25,715	$6.8	D

Explanation of Responses:

1. The American Depositary Shares reported in this row consist of restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on October 1, 2024 and vest and become exercisable according to following schedule: 25% on October 1, 2025, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on October 1, 2028.

2. The American Depositary Shares reported in this row consist of RSUs that were granted to the Reporting Person by the Issuer on April 10, 2025 vest and become exercisable according to following schedule: 25% on April 10, 2026, thereafter, in 12 equal quarterly installments of 6.25%, such that all RSUs reported in this row will be exercisable on April 10, 2029.

3. The options reported in this row were granted to the Reporting Person by the Issuer on November 11, 2021, and are fully vested and exercisable as of the date of this report.

4. The options reported in this row were granted to the Reporting Person by the Issuer on November 8, 2022, and vest and become exercisable according to following schedule: 25% on November 8, 2023, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on November 8, 2026.

5. The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable according to following schedule: 25% on June 14, 2024, thereafter, in 12 equal quarterly installments of 6.25%, such that all options reported in this row will be exercisable on June 15, 2027.

Remarks:

This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.

	/s/ Sigal Fattal	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)